DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses.
DNAtrix’s first product, DNX-2401 (tasadenoturev), is a modified common cold virus that selectively targets and kills cancer cells. DNX-2401 has demonstrated robust efficacy and safety in more than a decade of scientific and clinical research, including clinical studies across several tumor types.
DNX-2401 possesses unique characteristics needed for safety and efficacy.
- Novel Mechanism: oncolytic immunotherapies that kill tumor cells and trigger an antitumor immune response
- Versatility: Individual therapies can be engineered for a wide variety of cancers
- Excellent Safety: Demonstrated across multiple clinical studies
- Combinability: Excellent safety and ease of administration make them suitable for combination therapy with many classes of drugs
|Designation||Granting Organization||Date||Additional Information|
|PRIority MEdicines (PRIME)||European Medicines Agency (EMA)||July 27, 2016||Learn more >|
|Orphan Medicinal Product||European Commission||February 9, 2016||Learn more >|
|Orphan Drug||FDA||October 7, 2014||Learn more >|
|Fast Track Status||U.S. Food and Drug Administration (FDA)||June 17, 2014||Learn more >|
DNX-2401 is based on engineering stable genetic changes to adenovirus genomes to ensure safety and to enhance anti-tumor efficacy. Two stable genetic changes cause DNX-2401 to (1) replicate selectively in retinoblastoma (Rb) pathway deficient cells and (2) infect cells that express certain RGD-binding integrins more efficiently. Because virtually all tumor cells are defective in Rb function and already in the cell cycle, DNX-2401 replicates in and kills these tumor cells selectively and efficiently.
DNAtrix’s lead product, DNX-2401, demonstrates a potent anti-tumor mechanism of action by (1) replicating in human tumors (2) eliciting tumor necrosis and (3) triggering an immune response.